DRREDDY.NS - Dr. Reddy's Laboratories Limited
| Previous Close | 2,613.15 |
| Open | 2,601.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2,582.15 - 2,645.00 |
| 52 Week Range | 1,887.00 - 2,749.95 |
| Volume | 739,253 |
| Avg. Volume | 892,326 |
| Market Cap | 438.082B |
| Beta (3Y Monthly) | 0.05 |
| PE Ratio (TTM) | 27.48 |
| EPS (TTM) | 96.04 |
| Earnings Date | May 10, 2018 - May 14, 2018 |
| Forward Dividend & Yield | 20.00 (0.77%) |
| Ex-Dividend Date | 2018-07-17 |
| 1y Target Est | 2,587.45 |
- Business Wire•8 days ago
Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter store-brand equivalent of Prilosec® OTC Tablets, 20 mg, in the United States market as approved by the U.S.
- Simply Wall St.•12 days ago
An Examination Of Dr Reddy’s Laboratories Limited (NSE:DRREDDY)
I've been keeping an eye on Dr Reddy's Laboratories Limited (NSE:DRREDDY) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I Read More...
- Business Wire•21 days ago
Dr. Reddy's Laboratories Announces the Launch of Chlorthalidone Tablets, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton Tablets, approved by the U.S.
- Reuters•28 days ago
Indivior backs FY view, warns of generic rival hit; shares fall
Shares of drugmaker Indivior Plc fell as much as 10 percent on Wednesday, a day after the company lost a legal battle that will allow an Indian generic rival to sell a copycat version of its blockbuster film-based opioid addiction treatment. The company stuck to its full-year forecast on Wednesday, but warned it could take a hit if the rival drug from Dr. Reddy's Laboratories Ltd comes to market this year. Indivior's shares nearly halved in value on Tuesday and sank to an all-time low of 104.95 pence after a preliminary injunction blocking Dr. Reddy's from selling the generic was lifted by a U.S. court.
Reuters•28 days agoDr. Reddy's shares spike after favourable generic drug ruling
The U.S. Court of Appeals for the Federal Circuit lifted a preliminary injunction that blocked Dr. Reddy's from selling the generic, saying a lower court judge erred in granting the request. "As a result of today's ruling, Dr. Reddy's will resume its launch activities as soon as permitted," the Hyderabad-based generic drugmaker said https://www.bseindia.com/xml-data/corpfiling/AttachLive/1ee19eb7-226c-43e8-a8e5-7de9b377569a.pdf late on Tuesday. Investors welcomed the news, with shares of Dr. Reddy's reaching their highest in nearly two months - 2,655 rupees.
- Business Wire•28 days ago
Dr. Reddy's Laboratories Announces Favorable Outcome in Buprenorphine and Naloxone Sublingual Film Patent Litigation
Dr. Reddy’s Laboratories Ltd. announced today that the United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr.
- Business Wire•2 months ago
Dr. Reddy's Laboratories Announces the Launch of Atomoxetine Capsules, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera® Capsules in the United States market approved by the U.S.
- Zacks•2 months ago
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
- Simply Wall St.•2 months ago
Should We Worry About Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) P/E Ratio?
I am writing today to help inform people who are new to the stock market and want to learn about the link between company’s fundamentals and stock market performance. Dr Read More...
- Associated Press•2 months ago
Doctor Reddy's: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Hyderabad, India-based company said it had net income of 42 cents. The pharmaceutical posted revenue of $524 million in the period. Doctor Reddy's shares have fallen 13 percent ...
- Business Wire•2 months ago
Dr. Reddy’s Q2 & H1 FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2018 under International Financial Reporting Standards .
- Simply Wall St.•2 months ago
How Much is Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) CEO Getting Paid?
In 2001 Gunupati Prasad was appointed CEO of Dr Reddy’s Laboratories Limited (NSE:DRREDDY). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- Business Wire•2 months ago
Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market
Dr. Reddy’s Laboratories Ltd today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S.
- Business Wire•2 months ago
Dr. Reddy's Laboratories Announces the Sale of Its API Manufacturing Business Unit in Jeedimetla, Hyderabad
Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company. This divestiture is being done by way of slump sale and includes all related fixed assets , current assets, current liabilities, and its employees.
- Business Wire•2 months ago
Dr. Reddy's Laboratories announces the launch of Colesevelam Hydrochloride Tablets in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced that it has launched Colesevelam HCl Tablets, USP, a therapeutic equivalent generic version of WELCHOL Tablets in the United States market approved by the U.S.
- Business Wire•2 months ago
Dr. Reddy's to Release Q2 FY19 Results on October 26, 2018
Earnings call slated for October 26, 6:00 PM IST / 8:30 AM EDT
- Zacks•3 months ago
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Sale of Cloderm® (clocortolone pivalate) Cream, 0.1% Franchise to EPI Health, LLC
Dr. Reddy’s Laboratories Ltd. announced today that its wholly owned subsidiary Promius Pharma, LLC, has sold its rights of Cloderm® Cream, 0.1% and its authorized generic to EPI Health, LLC, an affiliate of EPI Group, LLC.
- Simply Wall St.•3 months ago
Who Are The Top Investors In Dr Reddy’s Laboratories Limited (NSE:DRREDDY)?
If you want to know who really controls Dr Reddy’s Laboratories Limited (NSE:DRREDDY), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock Read More...
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Launch of Imatinib Mesylate Tablets, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec Tablets in the United States market approved by the U.S.
- Business Wire•3 months ago
Dr. Reddy’s Laboratories Announces That It Has Regained Worldwide Rights to DFA-02
Dr. Reddy’s Laboratories Ltd. today announced the termination of the license granted to Armis Biopharma, Inc.
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Sale of Its Antibiotic Manufacturing Site and Its Related Assets in Bristol, Tennessee
Dr. Reddy’s Laboratories Ltd. today announced the closure of the sale of its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma Inc., a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.
- Zacks•3 months ago
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong
Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz Injection approved by the U.S.
- Zacks•4 months ago
The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Infosys, ICICI Bank and HDFC Bank
The Zacks Analyst Blog Highlights: Dr. Reddy'sLaboratories, Infosys, ICICI Bank and HDFC Bank
